Rhythm Pharmaceuticals, Inc. (RYTM)
| Market Cap | 6.45B +62.1% |
| Revenue (ttm) | 217.17M +58.7% |
| Net Income | -207.84M |
| EPS | -3.14 |
| Shares Out | 68.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 882,543 |
| Open | 95.79 |
| Previous Close | 96.23 |
| Day's Range | 93.24 - 96.76 |
| 52-Week Range | 55.31 - 122.20 |
| Beta | 1.94 |
| Analysts | Strong Buy |
| Price Target | 131.93 (+40.1%) |
| Earnings Date | May 5, 2026 |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic... [Read more]
Financial Performance
In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price target is $131.93, which is an increase of 40.10% from the latest price.
News
Rhythm Pharmaceuticals price target raised to $143 from $140 at Canaccord
Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $143 from $140 and keeps a Buy rating on the shares. The firm said the company delivered a topline
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...
Rhythm Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw $60.1M in revenue, driven by BBS and a strong U.S. launch of IMCIVREE for acquired HO, with over 150 start forms and positive payer response. International expansion advanced with EU approval and Japan NDA filing, supporting a robust outlook for 2026.
Rhythm Pharmaceuticals reports Q1 EPS (83c), consensus (86c)
Reports Q1 revenue $60.11M, consensus $56.07M. “The U.S and European approvals of IMCIVREE mark a transformational milestone for patients with acquired hypothalamic obesity who, until now, had no appr...
Rhythm Pharmaceuticals sees FY26 operating expenses $385M-$415M
Meeker added, “In addition, we continue to advance our MC4R agonism pipeline with upcoming data readouts from ongoing trials of setmelanotide in Prader-Willi syndrome and our weekly injectable, RM-718...
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- F...
Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data
Rhythm Pharmaceuticals (RYTM) announced the presentation of new data delivered by Rhythm and its partners at The Pediatric Endocrine Society Annual Meeting. “The data presented provide important longe...
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pedi...
Rhythm Pharmaceuticals’ Imcivree granted MAA in Europe for obesity
Rhythm Pharmaceuticals (RYTM) announced the European Commission, or EC, has expanded the marketing authorization for Imcivree – setmelanotide – to include the treatment of obesity and control of hunge...
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hyp...
Rhythm Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
IMCIVREE’s U.S. launch for acquired HO is underway, with expansion planned in Europe and Japan. Key pipeline updates include mid-year PWS data and phase III studies for new agents. The company is focused on rare MC4R pathway diseases, with strong cash reserves and a long-term vision for global leadership.
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra...
Rhythm Pharmaceuticals price target raised to $136 from $130 at RBC Capital
RBC Capital raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $136 from $130 and keeps an Outperform rating on the shares as part of the firm’s broader research
Rhythm Pharmaceuticals appoints Popovits to board of directors
Rhythm Pharmaceuticals (RYTM) announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. Popovits previously served as Chairman of the Boar...
Rhythm Pharmaceuticals Announces Changes to Board of Directors
-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical c...
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceut...
Rhythm Pharmaceuticals price target raised to $105 from $100 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $105 from $100 and keeps a Buy rating on the shares after the FDA approved
Rhythm Pharmaceuticals selects Pantherx Rare as pharmacy for Imcivree
PANTHERx Rare Pharmacy announced that it was selected by Rhythm Pharmaceuticals (RYTM) as the exclusive U.S. Pharmacy distribution partner for the expanded indication of IMCIVREE for adults and childr...
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
PITTSBURGH, March 20, 2026 /PRNewswire/ -- PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was se...
Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $149 from $139 and keeps a Buy rating on the shares after the company announced FDA
Rhythm Pharmaceuticals price target raised to $142 from $131 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $142 from $131 and keeps a Buy rating on the shares after the FDA approved Imcivree
Rhythm Pharmaceuticals price target raised to $155 from $152 at Citizens
Citizens raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $155 from $152 and keeps an Outperform rating on the shares. FDA approval for hypothalamic obesity substantially expands Imc...
Rhythm Pharmaceuticals trading resumes
19:05 EDT Rhythm Pharmaceuticals (RYTM) trading resumes
Rhythm Pharmaceuticals Transcript: Study update
IMCIVREE received FDA approval for acquired hypothalamic obesity, supported by phase III data showing significant BMI and hunger reductions. The launch targets a US population of about 10,000, with expanded sales and patient support teams, and ongoing efforts to secure broad payer coverage and international approvals.
Rhythm Pharmaceuticals trading halted, news pending
18:25 EDT Rhythm Pharmaceuticals (RYTM) trading halted, news pending